Treatment of Bacillary Angiomatosis with Multifocal Bartonella Infection or Evidence of Clinical Decompensation

Clinical Scenario

This protocol applies to patients with bacillary angiomatosis who present with multifocal Bartonella infection or signs of clinical decompensation — a severity pattern that distinguishes this population from those with mild, localised disease and calls for a more intensive management strategy.

Treatment Approach (Overview)

Guidelines recommend combination antibiotic therapy for this presentation, pairing an antibiotic active against Bartonella with a rifamycin-class agent. Initial therapy may need to be administered intravenously. The complete regimen — including agent selection, route, and duration — is available in the full protocol.

Treatment Goal

Response is assessed serologically: the target is at least a fourfold decrease in anti-Bartonella IFA IgG antibody titers, evaluated on sequential endpoint titers every 6 to 8 weeks during treatment.

Instant Access to Structured Evidence-Based Regimens

References

For severe Bartonella infections (i.e., patients with multifocal disease or evidence of clinical decompensation), combination therapy using erythromycin or doxycycline with a rifamycin class antibiotic is recommended (BIII); intravenous therapy may be needed initially (AIII).
For patients with positive or increasing antibody titers, but with clinical improvement, treatment should continue until at least a fourfold decrease in the antibody titers is documented (CIII).

View source ↗